Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
133.17
-0.77 (-0.57%)
Jun 6, 2025, 1:15 PM - Market open
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $10.36B in the quarter ending March 31, 2025, with 3.95% growth. This brings the company's revenue in the last twelve months to $42.34B, up 5.00% year-over-year. In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth.
Revenue (ttm)
$42.34B
Revenue Growth
+5.00%
P/S Ratio
5.50
Revenue / Employee
$371,439
Employees
114,000
Market Cap
231.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ABT News
- 9 days ago - Best Dividend Aristocrats For June 2025 - Seeking Alpha
- 10 days ago - Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery - PRNewsWire
- 10 days ago - Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story - Seeking Alpha
- 22 days ago - Abbott India's quarterly profit climbs 28% on strong demand - Reuters
- 22 days ago - Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes - PRNewsWire
- 4 weeks ago - US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease - Reuters
- 5 weeks ago - MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races - PRNewsWire
- 5 weeks ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC